Cite
HARVARD Citation
Blankenstein, S. et al. (2019). High response rates after neoadjuvant cytoreductive treatment with BRAF/MEK inhibition of prior unresectable regionally advanced melanoma, REDUCTOR trial. European journal of surgical oncology. 45 (2), pp. e6-. [Online].